BioSpace News Archive

The clinical study on ANG-3777 demonstrated a modest but not clinically significant difference in the placebo group’s estimated glomerular filtration rate.

Pennsylvania-based Ocugen has submitted an Investigational New Drug (IND) to the FDA to run a Phase III trial of India’s BBV152 (Covaxin), a vaccine against COVID-19.

Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.

Pasithea Therapeutics Corp. today announced that Pasithea Clinics, its wholly owned subsidiary, has administered intravenous (“IV”) ketamine therapy to its first patients.

Science 37, the Operating System for today’s more agile clinical trials and 3H Medi Solution Inc., a clinical trials solution leader in Japan today announced a collaboration to further decentralized clinical trials and accelerate the development of therapies.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2021 financial results prior to market open on Wednesday, November 3, 2021.

Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

Aetna®, a CVS Health® company (NYSE CVS), announced the launch of its designated Gene-based, Cellular, and Other Innovative Therapies™ (GCIT) network.

DiaCarta Inc.,today announced the publication of a study in PLOS ONE that demonstrates that DiaCarta’s ColoScape™ Xenonucleic Acid (XNA)-mediated quantitative real-time polymerase chain reactions (qPCR) clamping assay detects mutant cell-free DNA (cfDNA) from precancerous colorectal cancer (CRC) lesions and colorectal cancer.

GABAeron, Inc. GABAeron. today presented promising preclinical data on their first-in-class, iPSC-based cell therapy product for Alzheimer’s disease at the International Society for Stem Cell Research